Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Neuropharmacology. 2022 Aug 22;218:109233. doi: 10.1016/j.neuropharm.2022.109233

Fig. 8. The effect of ELB00824 on the inhibitory effect of oxaliplatin on cancer cell proliferation.

Fig. 8.

Human colorectal carcinoma cells (HCT116) in A or Human oral squamous carcinoma cells (HSC-3) in B were incubated 48 h with ELB (ELB00824) only, or with both oxaliplatin (0, 0.3, 1, 3, 10, 30, or 60 μM) and ELB00824 (0, 10, or 30 μM). The viable cell count (%) was determined using the CellTiter-Glo Luminescent Cell Viability Assay. Each plot represents the mean of three wells. IC50 is a quantitative measure that indicates the concentration of oxaliplatin is needed to inhibit cell viability by 50%.